Medication
Gabapentin
DIN 02388200 · Sivem Pharmaceuticals ULC Likely a generic
What it is
- Active ingredients
- Gabapentin — 600 mg
- Form and route
- Tablet · Oral
- Schedule
- PRESCRIPTION
- Authorised since
- 2012-06-26
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
- Neurontin
- Teva-Gabapentin
- Riva-Gabapentin
- Apo-Gabapentin
- Pro-Gabapentin
- Ach-Gabapentin
- GLN-Gabapentin
- Auro-Gabapentin Tablets
- Gabapentin
- Gabapentin
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Ontario Drug Benefit coverage
As of 31 July 2026Off-formulary interchangeable Part III-B
Ontario has designated this product interchangeable with a brand product, but it is not an ODB benefit — Part III-B, Off-Formulary Interchangeable. Ontario does not pay for it under the benefit list.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 600mg Tab and will substitute one for another at a pharmacy counter in Ontario.
- Ach-Gabapentin 02392526Accord Healthcare Inc
- Apo-Gabapentin 02293358Apotex Inc
- Auro-Gabapentin Tablets 02428334Auro Pharma Inc
- Gabapentin 02431289Sanis Health Inc
- Gabapentin 02432072Jamp Pharma Corporation
- GLN-Gabapentin 02410990Glenmark Pharmaceuticals Canada Inc.
- Neurontin 02239717BGP Pharma ULC
- Teva-Gabapentin 02248457Teva Canada Limited
Ontario lists 1 further product in this group that is not currently marketed in Canada. It is not shown.
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Nervous system
- ATC code
- N02BF01
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of N02BF01, see the WHO ATC/DDD Index.
Recalls and safety alerts
Recall matching is not available yet.
RxMonitor does not yet match Health Canada recalls to individual products — that arrives in a later release. Nothing on this page should be read as confirming that this medication has not been recalled.